METTL3 and cancer: In addition to FTO inhibitors, the inhibitor of METTL3, STM2457, as a highly efficient and selective inhibitor, with in vivo activity and therapeutic efficacy, marks the first evidence of the effectiveness of RNA methyltransferase inhibitors in cancer therapy.